The antirheumatic drug auranofin was recently shown to inhibit PRKCI and sensitize SCLC cells to sorafenib in vitro [21,22], highlighting a potential therapeutic avenue worth clinical exploration. The gene discussed is PRKCI; the disease is small cell lung carcinoma.